Program Manager, Global Devices
Hospira, Inc. (Formerly Abbott Laboratories)
Spearheaded non-DEHP conversion of all gravity and pump intravenous sets as part of a global strategy to increase this business by $78 million (144%) by 2012. This involved rationalizing the global product line, handling technical, regulatory conversion, and plant capacity issues. This also included personal development of a software application to support commercial efforts globally.Developed an in-house process to in-source the manufacture of plungers for an existing prefilled syringe package. This project has an ROI of over 80% and an annual savings of $1.0 million.Designed a new lyophilization stopper to reduce costs by over $600,000 per year compared to third party sourcing.Developed concept to reduce overall piece cost of a mature pharmaceutical closure by over 20% using cellular manufacturing.Identified root cause and magnitude of press-induced molded part vertical variability using solid modeling, finite element analysis, materials science and topography.